Evidence map›Paper›PMID 39265554›Full record

ArticleORL; journal for oto-rhino-laryngology and its related specialties2024

Unilateral Neck Treatment with either Surgery and/or Radiotherapy for Squamous Cell Carcinoma for the Tonsil.

Niema B Razavian, Joshua D Waltonen, Cole R Steber, Rachel F Shenker, Nelson H May, Jae H Yang, Claire M Lanier, Kathryn M Greven, Bart A Frizzell, Ryan T Hughes

Abstract read
In one paragraph

Article in ORL; journal for oto-rhino-laryngology and its related specialties, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Niema B RazavianDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA, nrazavia@wakehealth.edu.
Joshua D WaltonenDepartment of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Cole R SteberDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Rachel F ShenkerDepartment of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina, USA.
Nelson H MayDepartment of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Jae H YangDepartment of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Claire M LanierDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Kathryn M GrevenDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Bart A FrizzellDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Ryan T HughesDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStrategies for treatment of tonsil carcinoma are under active investigation. Limiting surgical and radiation treatment volumes to the primary tumor and ipsilateral neck in appropriately selected patients are one such approach. Here, we present our institutional experience with treatment through ipsilateral surgical or radiotherapeutic neck management.

methodsWe retrospectively reviewed our institutional database of patients with tonsil carcinoma treated from 2012 to 2020. Patients were included for analysis if they received definitive radiation therapy (RT), definitive surgery (S), or surgery with postoperative radiation therapy (S-PORT) and whose treatment volumes were limited to the primary tumor and involved/elective ipsilateral neck. Patients who received radiation and/or surgery to the contralateral neck (including those with bilateral nodal involvement), as well as patients with metastatic disease, were excluded. Clinical factors including T- and N-stage (AJCC 7th edition), and HPV status (by p16 and/or HPV DNA PCR) were recorded, as were pathologic factors (when applicable) including margin status, extracapsular extension (ECE), lymphovascular invasion (LVSI), and perineural invasion (PNI). Overall survival (OS), progression-free survival (PFS), and locoregional control (LRC) at 2 years were estimated using the Kaplan-Meier method.

resultsIn total, 71 patients were treated with unilateral neck approaches: S (n = 49), RT (n = 10), and S+PORT (n = 12). Among these patients, 32, 36, and 3 had T1, T2, and T3 disease, respectively. N-stage was N0, N1, N2a, N2b, and N3 in 22, 20, 5, 23, and 1 patient(s), respectively. Concurrent chemotherapy was administered in 12 patients. From those with recorded risk factors, 86% were HPV positive, 20% had LVSI, 7% had PNI, 13% had ECE, and 5% had positive margins. From a median follow-up of 27 months, local, regional, and distant failures occurred in 5, 6, and 5 patients, respectively. No contralateral neck failures were recorded. At 2 years, OS, PFS, and LRC were 92% (95% CI 85-99%), 85% (95% CI 75-95%), and 88% (95% CI 80-98%), respectively.

conclusionsIn patients with early T-stage tonsil carcinoma, treatment of the primary tumor and ipsilateral neck is associated with acceptable OS, PFS, and LRC. In this population, the risk of contralateral neck failure is likely very low regardless of primary treatment modality. Additional prospective studies are needed to determine the impact of limiting treatment extent, either surgical or radiotherapeutic, to the unilateral neck.

Indexed as

Tonsillar NeoplasmsAdultAgedCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedNeck DissectionNeoplasm StagingRetrospective StudiesRadiationSurgeryTonsilUnilateral

Identifiers

PMID39265554
PMCPMC11651319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.